tributyl(vinyl)tin | 20474-38-8

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机过渡后金属化合物
• 英文名称: tributyl(vinyl)tin
• 英文别名: tripropylvinyltin；Tripropyl-vinyl-stannan；tripropyl-vinyl stannane；Tripropyl-vinyl-zinn；tributyl(ethenyl)stannane；Tripropyl-vinyl-stannane；ethenyl(tripropyl)stannane
• CAS: 20474-38-8
• 化学式: C₁₁H₂₄Sn
• 分子量: 275.022
• InChiKey: WZLMEWCPYFUYEG-UHFFFAOYSA-N

物化性质

• 沸点：
  90 °C(Press: 8.2 Torr)
• 密度：
  1.131 g/cm3(Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  4.39
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  tributyl(vinyl)tin 在 CH₃COOH 作用下， 以16%的产率得到三正丙基锡乙酸酯
  参考文献：
  名称：

  Notes - Vinyl Derivatives of the Metals. VII. Preparation of Organotin Esters by Cleavage of Vinyltin Compounds

  摘要：

  DOI：

  10.1021/jo01095a621
• 作为产物：
  描述：

  四丙基锡 以 四氢呋喃 为溶剂， 生成 tributyl(vinyl)tin
  参考文献：
  名称：

  Notes - Vinyl Derivatives of the Metals. VII. Preparation of Organotin Esters by Cleavage of Vinyltin Compounds

  摘要：

  DOI：

  10.1021/jo01095a621

文献信息

• Anti-cancer agents and uses thereof
  申请人：Kelly Martha

  公开号：US20060270686A1

  公开（公告）日：2006-11-30

  The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A 1 is N or CR 1 ; A 3 is N or CR 3 ; A 5 is N or CR 5 ; R 1 , R 3 —R 6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.

  本发明涉及新化合物及其盐，它们的合成以及它们作为抗癌剂的用途。这些化合物包括式I的化合物： 和其溶剂化物、水合物和药用可接受盐，其中A 1 为N或CR 1 ；A 3 为N或CR 3 ；A 5 为N或CR 5 ；R 1 ，R 3 —R 6 和L在说明书中有定义；n为0或1；X为在环部分具有6-10个碳的可选择取代芳基，在环部分具有1-3个氮原子的可选择取代的6元杂芳基，在环部分具有0-4个氮原子且可选择具有1个硫原子或1个氧原子的可选择取代的5元杂芳基，或者在其中6元环与5元环或6元环融合的可选择取代的杂芳基，其中在每种情况下1、2、3或4个环原子是从氮、氧和硫中独立选择的杂原子。它们对广泛范围的癌症，特别是白血病、非小细胞肺癌和结肠癌有效。
• 喹啉类化合物、其制备方法、中间体、药物组合 物和应用
  申请人：上海医药集团股份有限公司

  公开号：CN105968115B

  公开（公告）日：2018-11-09

  本发明公开了喹啉类化合物、其制备方法、中间体、药物组合物和应用。本发明提供了一种如式1所示的喹啉类化合物、其药学上可接受的盐、溶剂化物、代谢产物、代谢前体或其药物前体。本发明的喹啉类化合物对酪氨酸激酶C‑Met有良好的抑制效果，可以用于制备预防、治疗或辅助治疗与C‑Met的表达或活性有关的多种疾病、尤其是肿瘤疾病的药物。
• [EN] IMIDAZOL-2-ONE COMPOUNDS USEFUL IN THE TREATMENT OF VARIOUS DISORDERS<br/>[FR] COMPOSES D'IMIDAZOL-2-ONE UTILES DANS LE TRAITEMENT DE DIVERS TROUBLES
  申请人：GLAXO GROUP LTD

  公开号：WO2005121122A1

  公开（公告）日：2005-12-22

  A compound of formula (I) wherein: R represents a group selected from: i) ii) iii) or iv) in which R6 is halogen, cyano, C1-4 alkyl or trifluoromethyl and p is 2 or 3 or R6 is halogen, cyano, C1-4 alkyl, C1-4 alkoxy, trifluoromethoxy or trifluoromethyl and p is 0 or 1; R1 represents hydrogen, halogen, cyano, C2-4 alkenyl, C1-4 alkyl optionally substituted by halogen, cyano or C1-4 alkoxy; R2 represents hydrogen or (CH2)qR7; R3 and R4 each independently are hydrogen or C1-4 alkyl; R5 represents : phenyl substituted by 1 to 3 groups independently selected from trifluoromethyl, C1-4 alkyl, cyano, C1-4 alkoxy, trifluoromethoxy, halogen, S(O)rC1-4 alkyl or a phenyl substituted by a 5 or 6 membered heteroaryl group optionally substituted by 1 to 3 groups independently selected from trifluoromethyl, C1-4 alkyl, cyano, C1-4 alkoxy, trifluoromethoxy, halogen or S(O)rC1-4 alkyl; naphthyl substituted by 1 to 3 groups independently selected from trifluoromethyl, C1-4 alkyl, cyano, C1-4 alkoxy, trifluoromethoxy, halogen or S(O)rC1-4 alkyl; a 9 to 10 membered fused bicyclic heterocyclic group substituted by 1 to 3 groups independently selected from trifluoromethyl, C1-4 alkyl, cyano, C1-4 alkoxy, trifluoromethoxy, halogen or S(O)rC1-4 alkyl or R5 is a 5 or 6 membered heteroaryl group substituted by 1 to 3 groups independently selected from trifluoromethyl, C1-4 alkyl, cyano, C1-4 alkoxy, trifluoromethoxy, halogen or S(O)rC1-4alkyl; R7 is hydrogen, C3-7 cycloalkyl, C1-4 alkoxy, amine, C1-4 alkylamine, (C1-4 alkyl)2amine, OC(O)NR8R9 or C(O)NR8R9; R8 and R9 each independently represent hydrogen, C1-4 alkyl or C3-7 cycloalkyl; A-B is a bivalent radical of formula (v) -CH=C(R11)- (vi) -C (R10)=CH- or (vii) -C(R12)(R10)-C(R11)(R13)- wherein R10, R11, R12 and R13 each independently are hydrogen or C1-4 alkyl; n is 1 or 2; q is an integer from 1 to 4; r is 1 or 2; or pharmaceutically acceptable salts and solvates thereof, process for their preparation and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.

  化合物的化学式（I），其中：R代表从以下选项中选择的基团：i）ii）iii）或iv），其中R6是卤素、氰基、C1-4烷基或三氟甲基，p为2或3，或者R6是卤素、氰基、C1-4烷基、C1-4烷氧基、三氟甲氧基或三氟甲基，p为0或1；R1代表氢、卤素、氰基、C2-4烯基、C1-4烷基，可选择地被卤素、氰基或C1-4烷氧基取代；R2代表氢或（CH2）qR7；R3和R4各自独立地是氢或C1-4烷基；R5代表：苯基，由1到3个基团独立选择的三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素、S（O）rC1-4烷基取代，或者由1到3个基团独立选择的三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或S（O）rC1-4烷基取代的5或6成员杂芳基苯基；由1到3个基团独立选择的三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或S（O）rC1-4烷基取代的萘基；由1到3个基团独立选择的三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或S（O）rC1-4烷基取代的9到10成员融合双环杂环基，或者R5是由1到3个基团独立选择的三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或S（O）rC1-4烷基取代的5或6成员杂芳基；R7是氢、C3-7环烷基、C1-4烷氧基、胺、C1-4烷基胺、（C1-4烷基）2胺、OC（O）NR8R9或C（O）NR8R9；R8和R9各自独立地代表氢、C1-4烷基或C3-7环烷基；A-B是化学式（v）的双价基团，其中-R11）-（vi）-C（R10）= CH-或（vii）-C（R12）（R10）-C（R11）（R13）-其中R10、R11、R12和R13各自独立地是氢或C1-4烷基；n为1或2；q为1到4的整数；r为1或2；或其药学上可接受的盐和溶剂，其制备方法及其用于治疗由速激肽介导的疾病和/或通过选择性抑制5-羟色胺再摄取转运蛋白的药物。
• Design, synthesis, and in vitro biological evaluation of novel 6-methyl-7-substituted-7-deaza purine nucleoside analogs as anti-influenza A agents
  作者：Cai Lin、Chenghai Sun、Xiao Liu、Yiqian Zhou、Muzammal Hussain、Junting Wan、Minke Li、Xue Li、Ruiliang Jin、Zhengchao Tu、Jiancun Zhang

  DOI：10.1016/j.antiviral.2016.01.005

  日期：2016.5

  order to improve treatment outcomes. To this regard, the design and synthesis of nucleoside analog inhibitors as potential anti-influenza A agents is a very active field of research nowadays. In this study, we designed and synthesized a series of hitherto unknown 6-methyl-7-substituted-7-deaza purine nucleoside analogs, and evaluated for their biological activities against influenza A virus strains,

  在甲型流感病毒的许多亚型中，甲型流感（H1N1）和甲型流感病毒（H3N2）目前在人类中传播（WHO报告2014-15）。在治疗上，对当前可用药物（金刚烷类和神经氨酸酶抑制剂）的病毒抗药性的出现提高了开发新型药物的警惕，这些新型药物可以解决病毒复制周期中的多种靶标，从而改善治疗效果。在这方面，作为潜在的抗甲型流感药的核苷类似物抑制剂的设计和合成是当今研究的一个非常活跃的领域。在这项研究中，我们设计和合成了一系列迄今未知的6-甲基-7-取代-7-脱氮嘌呤嘌呤核苷类似物，并评估了它们对甲型流感病毒H1N1和H3N2的生物活性。通过病毒抑制试验，我们鉴定了一些有效的化合物，其中化合物5x（H1N1和H3N2分别为IC50 = 5.88μM和6.95μM）和5z（H1N1和H3N2分别为IC50 = 3.95μM和3.61μM）表现出有效的抗甲型流感活性。基于选择性指数，我们认为化合物5x可以作为感
• ANTI-CANCER AGENTS AND USES THEREOF
  申请人：KELLY Martha

  公开号：US20090093479A1

  公开（公告）日：2009-04-09

  The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A 1 is N or CR 1 ; A 3 is N or CR 3 ; A 5 is N or CR 5 ; R 1 , R 3 -R 6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.

  本发明涉及新化合物及其盐，它们的合成方法以及它们作为抗癌剂的用途。这些化合物包括式I的化合物及其溶剂化物、水化物和药学上可接受的盐，其中A1为N或CR1；A3为N或CR3；A5为N或CR5；R1、R3-R6和L在规范中有定义；n为0或1；X是一个具有6-10个碳原子的环部分可选取代的芳基基团，一个具有1-3个氮原子的环部分可选取代的6元杂芳基基团，一个具有0-4个氮原子并可选地在环部分含有1个硫原子或1个氧原子的5元杂芳基基团，或者一个6元环与一个5元环或6元环融合的可选取代的杂芳基基团，在每种情况下，1、2、3或4个环原子是独立选择的氮、氧和硫杂原子。它们对广泛的癌症，尤其是白血病、非小细胞肺癌和结肠癌都有良好的治疗效果。